Innoviva Specialty Therapeutics, Inc.
Shruta Rege, Ph.D., serves as the Senior Vice President and Head of Global Regulatory Affairs and Development Operations at Innoviva Specialty Therapeutics, Inc. Previously, Shruta held the position of Vice President and Head of Global Regulatory Affairs and Pharmacovigilance Operations at Entasis Therapeutics. Experience also includes roles in Global Regulatory Affairs at Vertex Pharmaceuticals and a progression from Associate Director to Director of Global Regulatory Affairs at Shire. Additionally, Shruta began a career at Merck (Cubist Pharmaceuticals) as a Manager in Global Regulatory Affairs.
This person is not in any teams
Innoviva Specialty Therapeutics, Inc.
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious disease. Our approved treatments are indicated for use in life-threatening circumstances for seriously ill patients, and our investigational therapies are in development for patients fighting drug-resistant pathogens. Growing antimicrobial resistance to existing therapies represents an urgent threat to global public health, and is directly related to significant mortality rates and longer, more expensive hospital stays. We are proud to work with physicians, nurses, hospital pharmacists and administrators, and all who devote their time to caring for patients.